It has been four years since the official opening of the board on July 22, 2019. The board not only greatly improves the financing efficiency of science and technology enterprises, but also injects a strong impetus into the prosperity and development of China's capital market.

in order to further explore the opportunities brought by the sci-tech innovation board to the development of enterprises, on July 21, the financial afternoon tea column of national business daily invited Wu Wei, secretary of the board of directors of olin biology (SH688319, stock price 18.99 yuan, market value 7.713 billion yuan), to have in-depth discussions and exchanges on topics such as the bonus of the sci-tech innovation board system and the opportunities for specialization and new industries.

Wu Wei interviewee for figure

Listing helps the company develop in many ways

Olin Bio was established in 2009 and is a biopharmaceutical company specializing in the development, production and sales of human vaccines. The company's 2022 annual report shows that during the reporting period, the company achieved operating income of 0.547 billion billion yuan, an increase of 12.38 percent over the same period last year, mainly due to the continued growth in sales of adsorbed tetanus vaccine.

Wu Wei said in the program that as a high-tech enterprise focusing on the research, development, production and sales of human vaccines, Olin Bio successfully landed on the board using the fifth set of standards and became the first biopharmaceutical enterprise listed on the board using the fifth set of standards. It is worth mentioning that after the listing of Olin Bio, the sales of core products increased rapidly, becoming the first company in the fifth set of standard listed companies on the Science and Technology Innovation Board to achieve profitability in the first year of listing.

"Thanks to the flexible listing system of the board, Olin Bio has gained a rare access to financing. The listing not only eases the financial pressure on the company, but also accelerates the company's business expansion and technological innovation." Wu Wei mentioned.

Olin Bio's human vaccine track has a high investment in research and development, a long research and development cycle, and a high risk of research and development. With part of the IPO proceeds, Olin Bio developed a recombinant Staphylococcus aureus vaccine. The vaccine is an original Class 1 new drug that fills the gap in the world and establishes the company's "hard technology" image.

Strive to lead in the field of superbugs

It is understood that Staphylococcus aureus is the main pathogen of severe pneumonia, other respiratory infections, war injuries, burns, prosthetic joints, intensive care units and geriatrics infections and bacteremia. Because of its strong pathogenicity, many popular routes of transmission, and easy to produce drug resistance, methicillin Staphylococcus aureus (MRSA) has a fatality rate of up to 20%, which is called "super bacteria" by WHO ". According to data from Pfizer's clinical summary report, 23000 people die of drug-resistant Staphylococcus aureus infections in the United States every year. Clinical development and application of drug-resistant Staphylococcus aureus vaccines are urgent, but there is still no MRSA vaccine available in the world.

Wu Wei said that in the future, Olin Biology will cut into a series of vaccines for hospital infection through the technology platform and research and development experience accumulated in the research and development of recombinant Staphylococcus aureus vaccines, and strive to become a leader in the field of domestic superbacteria.

The 2022 Annual Report shows that Olin Bio's R & D investment doubled during the reporting period, with a total investment of more than 0.2 billion yuan on the R & D expense side and the capital side. During the reporting period, the company achieved the first export of the adsorbed tetanus vaccine, the Hib vaccine was re-registered and approved, the phase III clinical trial of the recombinant Staphylococcus aureus vaccine was officially launched, and the AC-Hib combined vaccine was ready to be declared for production. As of the disclosure date, the company's recombinant Staphylococcus aureus vaccine has achieved clinical enrollment in many hospitals across the country, and the application for production registration and marketing license submitted by the AC-Hib combined vaccine to the Food and Drug Administration has been accepted.

Wu Wei said, "In the future, we hope to create better cash profits with better performance and give back to shareholders".